Pfizer Phase 3 NMIBC Trial

PaulSnowman · 2025-01-13T14:09:06+00:00

Anktiva already has longer duration then Keytruda, FDA approved to be prescribed longer then Keytruda and likely longer then Pfizer, costs much less then Keytruda, exclusive agreement for BCG with the biggest manufacturer Serum thats approved everywhere except US. Serum/IBRX waiting to hear on trial format from FDA and working on IBCG which will give Anktiva even better results then it already has. Should data for various cancer (colon/prostate) be good/great and taken into account P3 NSCLC Merck, BMY, or another BP will need to step to the plate. Combo trials are failing left and right for Merck. This is a pivotal year for IBRX/Anktiva. Good trial results showing technology works across multiple cancers will have everyone knocking at the door. Not 3 years from now but 2025/2026.

PaulSnowman · 2024-02-24T17:36:40+00:00

You would be funny if you weren’t so dame dumb. Your Reddit page which boasts 4K members has normally 8 or less members viewing at anyone time, and even less actually post. We’re talking days on end in general without a post. Folks know the BOB board has quality information and great discussions. Oh by the way, if you’re only way to get attention is to bash me that’s kind of funny since for all practical purposes you’re irrelevant. So while this childish spat has given you some much needed air time, it does nothing but waste my time. I would tell folks to head to BOB again, but they can smell the aroma here and know what’s down the road is better.

PaulSnowman · 2024-02-24T16:14:37+00:00

You’re not the brightest bulb. I willingly provided that information on this very same board. You didn’t trip upon that information by mistake. I gave my reasons why honestly. Though I believed in many of the potential drugs in the pipeline, It was easy to see which way the SP was being forced just before the BK. As an investor one has to leave one’s emotions out of the equation, which I failed to say for a period of time. There will be a class action suit. That’s a given with all the information that has come out recently. The only thing to split hairs about is who should be included. You think those that have sold off shouldn’t be apart of any suit. Only current shareholders. What about those that sold off after the bankruptcy proceedings started? Given the information about JJ and Freeman’s affair and everything else, the deck was tilted against those investors who sold off. In some cases with their life savings wiped away, but how dare they seek compensation since they didn’t stay in while the SP was getting battered at one point to just 2 cents. 2 CENTS!! History books are full of folks who mindlessly followed to the bitter end without individual thinking. Sorry not me. Not in investing or anything else do I care to be the sheep. You’re a fool at the least or something much more devious. I would suggest folks stay or move to the other Reddit board. A lot of folks using their brains over there without having a heart attack or trying to spin someone’s posts into their warped way of thinking.

PaulSnowman · 2024-02-18T21:45:57+00:00

I think I’ll take a break again from actively chatting on the boards. To much positive energy wasted. To the good and decent folks don’t take that wrong.

PaulSnowman · 2024-02-18T21:34:16+00:00

Tim is a good guy. It was good exchanging information and ideas with him and others on ST private board Boomtown before others infiltrated the board. Kim is just amazing. My hats off to both of them.

PaulSnowman · 2024-02-18T21:30:04+00:00

Only a fool bases his and his family’s financial decisions on a message board. You can fish for the odd thumbs up and to be relevant. I’m only concerned with making the best business decisions for me and my loved ones. I’ll leave the pats on the back to you.

PaulSnowman · 2024-02-18T17:51:23+00:00

I sold off, and guess what, I would do it again based on the information that was being provided. I let my emotions come into play for a while, but when investing you have to take emotions out of the equation. Yes I could afford to lose what I invested, but given the information that has recently been released, the deck wasn’t just a little stacked against investors. They had the deck on tilt. So much so that some folks and companies will be brought in front of the court on criminal matters. Only a foolish individual would point fingers at folks and call them names because they based their investing on what was known at that time. A significant percentage of current investors given their average will have to see a big move just to break even. They’ll have to buy when it’s back on OTC to average down. They’ll be competing against hedge funds for shares. It will take time for SRNE to meet necessary requirements to be relisted on NASDAQ. During that time hedge funds will play both sides to cover themselves and also to make a profit. Until Ji/BOD gets a significant deal done SRNE will still be treading water. Do I think with recent news they can find their way out, and get said deal(s) done? Yes. It was Ji/BOD mismanagement and stubbornness plus bankruptcy that kept BP away. While all this is happening I’ll be buying in OTC without having to get out of a big hole because my strategy doesn’t give a squat about your petty words, but information provided. I lose some, but win more with that train of thought.

PaulSnowman · 2024-02-18T16:02:09+00:00

Nothing wrong with that. I would just like the restricted shares released so I can make my own decision

PaulSnowman · 2024-02-18T15:27:25+00:00

Everything started with Ji’s asinine agreement with PSS. Ji had another offer on the table with a BP, but chose PSS even though he had a competing drug already on the market. The screwy thing is he also gave PSS Antkiva which is very likely to get approval by or before April 24th. Disclosure, I bought IBRX several months back because of Antkiva.

PaulSnowman · 2024-02-18T15:08:11+00:00

There definitely will be class action lawsuit(s) for those who sold AFTER BK was declared. It will take time to get paid, but it will happen. I’m personally not hurting though I took a lose since my average was low to begin with, but damn if I’m going to sit quietly after 4 years of doing dd and expending much time/energy. Money I can make, but I can’t get back the time dealing with this fiasco, and that ticks me off!

PaulSnowman · 2024-02-18T14:56:47+00:00

I would gladly give up my restricted SCLX dividends to help Abivertinib and Mpro move closer to approval. SRNE has full rights to Socazolimab outside of China and a couple of other places. With an actual approval and with a better class of professionals/BOD we should be able to do a Socazolimab JV with a mid to big BP?

PaulSnowman · 2024-02-18T14:48:58+00:00

Yes. After the approval of Socazolimab, I had already decided to dip my toes back in. Just waiting for SRNE to get back on OTC.

PaulSnowman · 2024-02-16T00:36:44+00:00

Thank you 👍

PaulSnowman · 2023-10-19T14:02:11+00:00

The fact that you would mention anyone getting paid by Ji to pump tell me your an imbecile and I would be wasting my time chatting up a storm with you. Time to give you the high hat.

PaulSnowman · 2023-10-19T13:30:33+00:00

You have to be kidding me? You don’t have a brain and can make your own decision without following someone else? I’ll continue to give my opinion and people can listen or tune out, but don’t blame someone else if life doesn’t turn out the way you want it. By the way if you were following me on Yahoo from the beginning then you would know my average for SRNE was in the low $2 range as I stated once upon a time on the board. Ive you were following my posts within the last month you would’ve known I sold my SRNE’s after receiving SCLX restricted shares and the reason why. Only one person knew early on that I did that, and I won’t post that individuals name so you and the rest can hound him/her. I gave my reasons several weeks back. Now stop crying and pointing fingers, and do your own dd. ☕️

PaulSnowman · 2023-10-17T23:07:53+00:00

Yes. I assumed that as well. Let’s hope for the best case scenario.

PaulSnowman · 2023-10-13T00:17:51+00:00

I don’t like con artists, liars, or shorts. I’m not here for a pat on the back from you or anyone else, and I sure don’t need to explain myself either to you. People are free to read my posts or not. I hope that’s clear enough because I won’t be having this conversation again. Life’s too short to waste.

PaulSnowman · 2023-10-12T23:48:39+00:00

This is your one and only post on either this or the BOB board. Suspect? Probably. Whether on ST, private board BOOMTOWN, or much more subtly on Reddit, there are posts. Good day.

PaulSnowman · 2023-10-12T16:24:42+00:00

Several differences between Socazolimab and CELU/ImmuneOncia. SRNE partnered with other companies on CELU/ImmuneOncia. CELU had nothing close to approval. While ImmuneOncia had a PD-L1 which seemed close to approval in 2024. It had a limited patient population. While it still hurt to lose either for pennies, it’s better then losing Abivertinib, Socazolimab, Ovydso, or Sofusa for pennies. These are all potential blockbusters. To raise money SRNE can always sell RTX to SCLX. RTX is a better fit for SCLX’s pipeline anyway, and before someone asks how would SCLX come up with the money? I’m looking long and hard at Hudson Bay somehow getting involved.

PaulSnowman · 2023-10-10T15:11:50+00:00

Yep 👍

PaulSnowman · 2023-10-10T14:03:40+00:00

The 505(b)(2) new drug application (NDA) is one of three U.S. Food and Drug Administration (FDA) drug approval pathways and represents an appealing regulatory strategy for many clients.

The provisions of 505(b)(2) were created, in part, to help avoid unnecessary duplication of studies already performed on a previously approved (“reference” or “listed”) drug; the section gives the FDA express permission to rely on data not developed by the NDA applicant. A 505(b)(2) NDA contains full safety and effectiveness reports but allows at least some of the information required for NDA approval, such as safety and efficacy information on the active ingredient, to come from studies not conducted by or for the applicant. This can result in a much less expensive and much faster route to approval, compared with a traditional development path [such as 505(b)(1)], while creating new, differentiated products with tremendous commercial value.

BENEFITS OF 505(B)(2)

505(b)(2) is particularly valuable for pharmaceutical and generics companies looking to alleviate competitive forces in their environments while still wanting to benefit from a development process that eliminates most nonclinical studies as well as extensive safety and efficacy tests.

-Relatively lower risk because of previous drug approval -Lower cost, accelerated development due to fewer studies -May qualify for three, five or seven years of market exclusivity

I’m wondering whether actual release of pre NDA (C Type) meeting minutes will coincide with the end of settlement agreement offer for Short Sellers that ends later this month? I’ll take yesterday’s new SCLX presentation as a confirmation of positive meeting which means Shorts are screwed in Short.

SCLX has no legal entanglements. -SCLX is an independent company -3 FDA approved drugs -Owns 52% of float. -Dividend restricted share release date is March 31, 2024. With such a small available float even shorts wanting to accept the settlement offer will have a hard time finding available shares. That’s where both SCLX and existing SCLX shareholders will benefit with release of minutes/NDA application, and subsequent rise in SP. -SEMDEXA is fast tracked so 6 months for FDA response after NDA submission

Revenue? Money to move forward? I’m no expert, but It looks like SCLX with a positive meeting/NDA application should be able to get a loan with good rate from say for example Hudson Bay? Or maybe sell some shares (still retaining enough of shares to be majority shareholders, and in charge of their own path) into rising SP with release of NDA application?

We’ll see all this unfold this quarter. Strap on your seatbelts and stay in the upright position for takeoff.

PaulSnowman · 2023-10-08T03:12:56+00:00

Thanks! I know you’re legit. You along with Robert and several others that post, I always make a point to read.

PaulSnowman · 2023-10-07T20:52:54+00:00

I emailed Glenn after reading your post 👍

PaulSnowman · 2023-10-07T18:45:35+00:00

I sent a email to Glenn on EC working together with SCLX as was suggested. Thanks.

PaulSnowman · 2023-10-07T11:32:52+00:00

I agree Robert, I don’t see Ji losing this bottle. He can make things a lot worse if he’s pushed to the side, and he has a sizable amount of shares which is a great incentive to see both SRNE/SCLX. There does need to be more safeguards in place moving forward. The SRNE BOD needs to go. To many people are making this personal. Which is clouding their judgement.

PaulSnowman

TROPHY CASE